Moreover, PTEN appeared to play a causal role in determining pharmacological interactions between pathway inhibitors, as genetic manipulation of PTEN expression in melanoma cell lines, dramatically altered the functional response to combined MEK/mTOR inhibition. The gene discussed is MAP2K7; the disease is melanoma.